No profile data available.
Kiora Pharmaceuticals, Inc. (KPRX) is a healthcare company in the eye treatment pharmaceuticals industry, based in Encinitas, United States, with about 13 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$10.84 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $11.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Kiora Pharmaceuticals reported $0 in revenue for fiscal year 2025, down 100.0% from $16.00 million in fiscal year 2024. In Q2 2026 revenue was $0.
$11.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Okyo Pharma Limited (OKYO), Aldeyra Therapeutics, Inc. (ALDX), Hyperion DeFi, Inc. (HYPD), Kala Bio, Inc. (KALA).